IP Group plc (IPO) AI Stock Analysis

• Market Cap: £450.55M
• Dividend Yield: N/A
• Average Volume (3M): 2.98M
• Price to Earnings (P/E): 8.1
• Beta (1Y): 1.31
• Revenue Growth: N/A
• EPS Growth: 33.10%
• Country: UK
• Employees: 69
• Sector: Financial
• Sector Strength: 70
• Industry: Asset Management
• EPS (TTM): 0.12
• Shares Outstanding: 883,427,600
• 10 Day Avg. Volume: 3,376,057
• 30 Day Avg. Volume: 2,975,893
• PEG Ratio: -0.06
• Price to Book (P/B): 0.55
• Price to Sales (P/S): 12.04
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £105.00
• Price Target Upside: 81.98% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.06
• Revenue Forecast (FY): £63.70M

• Rating: 50 Neutral
• Price Target: 53.00 p ▼(-8.15% Downside)
• Action: Reiterated Date: 03/19/26
• Date: Action: Reiterated 03/19/26

The score is held back primarily by volatile operating performance and persistently weak cash generation despite a 2025 profitability rebound, while the balance sheet provides stability but not enough to offset cash-flow concerns. Technicals are also soft with the stock below longer-term moving averages and negative MACD. These are partially balanced by a low P/E valuation and a mixed-but-constructive earnings update featuring portfolio progress, higher proceeds, and ongoing buybacks.

Positive Factors

Strong liquidity buffer

A gross cash balance of GBP 237m and materially higher cash proceeds provide durable financial flexibility to support follow-on funding, bridge portfolio companies through development cycles, and pursue exits without forced disposals. This liquidity underpins operations and strategic optionality over months.

Proven exit upside

Delivering a 50x return from the Hinge Health IPO demonstrates IP Group's ability to commercialise university-derived technology and generate outsized realizations. This track record reinforces the firm’s company-building model and improves prospects for future high-value exits and mandate wins.

Shareholder-aligned capital allocation

A program retiring ~15% of capital indicates active capital allocation to enhance shareholder value and support NAV per share. Disciplined buybacks can be a durable lever to concentrate returns for remaining shareholders and signal management confidence in portfolio valuation.

Negative Factors

Weak cash generation

Persistent negative operating cash flow across multiple years implies reported profits are often not cash-backed, increasing reliance on asset sales, fair-value uplifts or external funding. Weak cash convertibility limits reinvestment capacity and heightens sensitivity to market exits over the medium term.

Earnings and revenue volatility

Multi-year swings from strong profits to sizable losses, then a rebound, indicate earnings are driven by lumpy realizations and revaluations rather than stable operating performance. This volatility complicates forecasting, return-on-equity consistency, and the durability of reported profitability for investors and partners.

Portfolio execution risks

Clinical trial failures and valuation impairments (e.g., Istesso miss, Oxa write-down) materially reduce potential exit values and can force write-offs or extended timelines. Such idiosyncratic setbacks are structural risks for a VC-style IP commercialiser and can erode NAV and exit cadence.

IP Group plc Business Overview & Revenue Model

Company Description

IP Group Plc is a private equity and venture capital firm specializing in seed, early stage, start-up, incubation, growth capital, and mature financing. The firm also provides seed capital financing to spin out companies from the universities. It seeks to invest in the life sciences, physical sciences, energy & renewables, medical equipment and supplies, healthcare, technology, cleantech, intellectual property, pharmaceuticals & biotechnology, information technology & communications, and chemicals & materials. It also provides support for its university partners' intellectual property commercialization activities, as well as in the identification of intellectual property. It typically invests between £0.5 million ($0.75 million) and £1 million ($1.50 million) per investment. The firm prefers to takes equity positions in its portfolio companies. IP Group Plc was founded in 2001 and is based in London, United Kingdom with additional offices in Wilmington, Delaware; London, United Kingdom; Oxford, United Kingdom; Hong Kong S.A.R., Hong Kong and Melbourne, Australia.

How the Company Makes Money

IP Group primarily makes money through returns generated from its investment portfolio rather than through operating revenue from selling products itself. Key earnings drivers include: (1) Realisations and exits: profits from selling equity stakes in portfolio companies via trade sales, secondary share sales, or public market disposals following IPOs/listings; (2) Fair value gains: increases in the assessed fair value of holdings in portfolio companies, which can contribute to reported gains when valuations rise (noting these are subject to revaluation and market conditions); (3) Dividends and distributions: income received when portfolio companies pay dividends or when funds/vehicles in which IP Group invests make distributions; (4) Other investment-related income: if applicable, interest income on cash and any shareholder loans or similar instruments provided to portfolio companies. The company’s ability to generate earnings depends materially on capital markets conditions, the timing and pricing of exit opportunities, portfolio company performance, and the success of commercialising university-derived intellectual property. Specific significant partnerships or counterparties contributing to earnings are null.

IP Group plc Financial Statement Overview

Summary

Financials are mixed: the balance sheet is relatively resilient with modest leverage and a large equity base, but earnings and revenue have been highly volatile with multi-year losses (2022–2024) despite a return to positive net income in 2025. Cash generation remains a key weakness, with mostly negative operating cash flow (including 2022–2025) and limited free-cash-flow improvement, raising concerns about earnings quality and durability.

Income Statement

Earnings have been highly volatile: profitability was very strong in 2020–2021, followed by large losses in 2022–2024, and then a return to positive net income in 2025. Revenue has been unstable and swung negative for multiple years, which makes trend-based growth and margin quality difficult to rely on. The 2025 turnaround is a clear positive, but the multi-year track record of losses and sharp revenue declines keeps the score below average.

Balance Sheet

The balance sheet looks relatively resilient, with modest leverage across the period (debt-to-equity generally low) and a large equity base. Debt levels are manageable and have not overwhelmed the capital structure, which provides flexibility through earnings drawdowns. The key weakness is return on equity, which was materially negative during 2022–2024 before turning positive in 2025, highlighting sensitivity of equity value to investment/valuation outcomes.

Cash Flow

Cash generation has been weak and inconsistent. Operating cash flow was negative in most years (including 2022–2025), and free cash flow was negative in several years with a sharp deterioration in 2020; 2025 shows free cash flow at roughly breakeven but not meaningfully positive. The gap between reported profitability (positive net income in 2025) and negative operating cash flow raises questions about the durability and cash convertibility of earnings.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	44.90M	-179.50M	-154.60M	-700.00K	95.10M
Gross Profit	44.40M	-179.50M	-154.60M	-302.00M	490.40M
EBITDA	71.70M	0.00	-179.90M	-343.70M	461.40M
Net Income	66.80M	-205.60M	-171.30M	-341.50M	448.50M
Balance Sheet
Total Assets	1.10B	1.15B	1.41B	1.56B	1.88B
Cash, Cash Equivalents and Short-Term Investments	16.50M	285.60M	226.90M	241.50M	321.90M
Total Debt	119.70M	150.00M	156.40M	101.80M	71.80M
Total Liabilities	123.50M	198.70M	221.30M	181.70M	141.20M
Stockholders Equity	975.10M	966.00M	1.20B	1.38B	1.74B
Cash Flow
Free Cash Flow	0.00	-25.10M	-17.90M	-23.80M	10.30M
Operating Cash Flow	-14.50M	-25.10M	-17.90M	-23.50M	10.50M
Investing Cash Flow	-32.10M	82.90M	-4.40M	-2.30M	26.30M
Financing Cash Flow	-52.50M	-42.90M	34.70M	8.80M	-58.30M

IP Group plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 57.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IPO, the sentiment is Negative. The current price of 57.7 is above the 20-day moving average (MA) of 52.01, above the 50-day MA of 55.74, and above the 200-day MA of 56.63, indicating a bearish trend. The MACD of -1.33 indicates Negative momentum. The RSI at 44.94 is Neutral, neither overbought nor oversold. The STOCH value of 37.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IPO.

IP Group plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FSG	73 Outperform	£411.24M	7.48	44.99%	5.73%	―	―
REC	72 Outperform	£96.72M	7.57	30.24%	8.61%	-11.43%	-17.65%
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
MERC	67 Neutral	£116.97M	21.20	1.79%	3.29%	-9.37%	―
ICGT	66 Neutral	£805.59M	-13.06	5.07%	2.47%	66.53%	100.92%
GROW	63 Neutral	£785.81M	2.30	8.81%	―	11.00%	―
IPO	50 Neutral	£450.55M	8.09	7.16%	―	―	33.10%

IP Group plc Corporate Events

IP Group returns to profit as Pfizer deal and tech exits lift NAV and fund buybacks

IP Group plc reported a return to profitability in 2025 as net asset value per share rose 13% to 110.4p, driven largely by the recognition of £128.2m in discounted future royalty and milestone income following Pfizer’s acquisition of obesity-drug developer Metsera. The group now has meaningful economic exposure to Pfizer’s GLP-1 obesity franchise, while its portfolio benefited from positive Phase 2b results for PF’3944, strong capital raising by investee companies and a growing pipeline of AI-related technologies.

The company generated £68.1m of cash from exits, including the NYSE flotation and full disposal of digital musculoskeletal clinic Hinge Health and the sale of Monolith AI to CoreWeave Inc., supporting a £75m share buyback that retired 9% of its share capital. IP Group maintained a robust balance sheet with £211m in gross cash, continued to build third-party funds under management via Parkwalk and a new Northern Universities Venture Fund, and expanded its role in early-stage UK investing through a new mandate with Aberdeen, underscoring its position as a leading university IP investor and its focus on long-term shareholder value.

The most recent analyst rating on (GB:IPO) stock is a Hold with a £56.00 price target. To see the full list of analyst forecasts on IP Group plc stock, see the GB:IPO Stock Forecast page.

IP Group sets date for 2025 results and schedules online investor briefing

IP Group plc, the UK based early stage science and technology investor, will publish its full-year results for the period ended 31 December 2025 on 17 March 2026 via the London Stock Exchange’s news service and its website. The timing underscores the group’s role as a listed gateway for exposure to high-growth innovation in healthtech, deeptech and cleantech.

The company’s leadership will host a live online investor presentation on 17 March 2026 at 9 a.m. through the Investor Meet Company platform, with opportunities for shareholders to submit questions before and during the event. By engaging retail and institutional investors through an accessible digital forum, IP Group is signalling an emphasis on transparency and active communication ahead of a potentially closely watched set of annual results.

The most recent analyst rating on (GB:IPO) stock is a Hold with a £56.00 price target. To see the full list of analyst forecasts on IP Group plc stock, see the GB:IPO Stock Forecast page.

IP Group boosts AI mobility exposure as Oxa raises $103m in Series D

IP Group said portfolio company Oxa Autonomy, a leader in autonomous vehicle technology, has completed the first close of its Series D funding with $103 million raised. The round was led by a $50 million commitment from the National Wealth Fund and included participation from NVIDIA’s venture arm NVentures, IP Group, its Hostplus managed funds and bp Ventures.

The new capital will support Oxa’s drive to commercialise Industrial Mobility Automation, targeting repetitive industrial driving tasks with its “universal AI driver” platform. IP Group invested a combined $35 million from its balance sheet and Hostplus funds, and now holds an undiluted 10.6% stake in Oxa directly plus 9.7% via managed funds, deepening its exposure to a leading private AI player in mobile autonomy.

The most recent analyst rating on (GB:IPO) stock is a Hold with a £56.00 price target. To see the full list of analyst forecasts on IP Group plc stock, see the GB:IPO Stock Forecast page.

IP Group portfolio company Microbiotica posts strong Phase 1b data for ulcerative colitis drug

IP Group said its portfolio company Microbiotica has reported strong Phase 1b data for MB310, an oral precision microbiome therapy targeting ulcerative colitis. Microbiotica develops live biotherapeutic products designed to modulate the gut microbiome, and IP Group holds an undiluted 16.7% stake in the company, valued at £13.9m as of 30 June 2025.

In a 29-patient randomised, placebo-controlled study, MB310 met primary and secondary endpoints, showing a safety profile comparable to placebo and robust engraftment of all eight bacterial strains. Clinical remission was achieved in 63.2% of MB310-treated patients versus 30.0% on placebo, with all treated patients entering follow-up remaining in remission and showing complete resolution of rectal bleeding.

The trial also showed improvements in histological markers of mucosal damage and reductions in faecal calprotectin, supporting a disease-modifying mechanism via restoration of the gut barrier and immune regulation. Microbiotica plans an adaptive Phase 2/3 programme in combination with standard anti-inflammatory or immune-modulatory agents and is exploring partnering and financing options to fund later-stage development and potential commercialisation.

For IP Group, the results underline the value of its exposure to microbiome-based therapeutics and validate Microbiotica’s clinic-first discovery platform, which leverages clinical data to identify beneficial bacterial consortia. If larger trials confirm these findings, MB310 could enhance Microbiotica’s and IP Group’s strategic positioning in innovative treatments for inflammatory bowel disease and potentially improve outcomes for ulcerative colitis patients seeking long-term remission without immune suppression.

The most recent analyst rating on (GB:IPO) stock is a Hold with a £56.00 price target. To see the full list of analyst forecasts on IP Group plc stock, see the GB:IPO Stock Forecast page.

IP Group Warns of Writedown After Pulmocide Halts Phase 3 Opelconazole Trial

IP Group has flagged a likely writedown in the value of its stake in Pulmocide after the portfolio company terminated its Opera-T Phase 3 trial of the antifungal treatment opelconazole in patients with refractory invasive pulmonary aspergillosis. Pulmocide, in which IP Group holds a 12% interest currently valued at £28.1m, will now review the unblinded trial data to assess future options for the programme, while IP Group plans a significant reduction in the asset’s carrying value as part of its year-end process but maintains that its broader pipeline of new and maturing investments and licence portfolio underpins its confidence in delivering medium-term returns for shareholders.

The most recent analyst rating on (GB:IPO) stock is a Hold with a £59.00 price target. To see the full list of analyst forecasts on IP Group plc stock, see the GB:IPO Stock Forecast page.